The company offers its products to medical centers, reference labs, government institutions, and community hospitals through a network of sales force and distributors. AdvanDx uses its proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform, which employs a unique Whole Cell Analysis (WCA) approach to pathogen identification. This technology enables fast and highly accurate single cell analysis for bacterial species identification in samples from patients with critical infections. AdvanDx is the market leader in molecular testing of positive blood cultures, providing pathogen identification results 48 to 72 hours earlier than conventional testing methods. Clinical studies show that early, appropriate antibiotic therapy for patients with bloodstream infections using AdvanDx's PNA FISH® tests reduces patient mortality, shortens length of stay (LOS), and lowers hospital costs.